Skip to main content
TrimSoMoEverything GLP-1, in one place
Independent GLP-1 Weight-Loss & Provider Guide

Check a GLP-1 company before you start.

Compare FDA-approved weight-loss medications, check BMI eligibility, and verify telehealth clinics.

Search 162 GLP-1-related FDA warning letters and 2,273 NPPES records with an obesity medicine taxonomy across 50 states, DC and Puerto Rico from public federal records.

Official Label Database

FDA-approved GLP-1 medications for weight loss

Filter by weekly injection, daily oral tablet, or active ingredient. Direct facts from FDA-approved labels.

Full label comparison table
Filter by:
Weekly InjectionFDA-approved

Wegovy

semaglutide

Dosing:Once weekly, subcutaneous
Form: Injection: prefilled, single-dose pen
Weekly InjectionFDA-approved

Zepbound

tirzepatide

Dosing:Once weekly, subcutaneous
Form: Injection: single-dose pen or single-dose vial; multi-dose vial or single-patient-use KwikPen
Daily Oral TabletFDA-approved

Wegovy Tablets

oral semaglutide

Dosing:Once daily (morning, empty stomach)
Form: Oral: 1.5 mg, 4 mg, 9 mg, and 25 mg tablets
Daily Oral TabletFDA-approved

Foundayo

orforglipron

Dosing:Once daily (with or without food)
Form: Oral: film-coated tablets (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg)
Interactive Tool

BMI & GLP-1 Indication Screener

Check whether your Body Mass Index (BMI) matches FDA label criteria for chronic weight management medications.

Height5 ft 8 in
Weight205 lbs
100 lbs275 lbs450 lbs
Calculated BMIAdult BMI
31.2kg/m²

Obesity (BMI ≥ 30.0)

31.2
15.018.525.030.0+40.0
UnderweightHealthy ZoneOverweightObesity
Meets FDA Label Indication Threshold

Based on official FDA prescribing information (BMI ≥30, or BMI ≥27 with comorbidity), this matches labeled indication criteria for weight management GLP-1 medications.

Healthy BMI Target (18.5–24.9):121 – 163 lbs

Current weight is ~42 lbs above the standard normal BMI threshold.

Educational Notice: Calculated instantly in your browser; no personal health information is stored or transmitted. This screening tool is based on official FDA medication labels for chronic weight management and is for educational reference only, not medical diagnosis or advice. Only a licensed healthcare provider can evaluate your medical history and determine appropriate treatment.

Interactive Decision Suite

Patient Decision Tools & Consultation Prep

Calculate estimated out-of-pocket costs with manufacturer savings cards, and generate your personal clinical discussion sheet.

All Tools Hub
Interactive Decision Tool

GLP-1 Insurance & Savings Card Cost Estimator

Estimate your realistic out-of-pocket monthly expense and determine manufacturer copay card eligibility rules.

Prior Authorization Guide →

Selected: Zepbound (Tirzepatide weekly injection). List price before insurance or coupons: ~$1,060 / 28-day supply.

Estimated Monthly Out-of-Pocket
$25 – $150 / month
Fully Eligible for Savings Card

Your commercial insurance plan covers anti-obesity medications on its formulary.

  • Manufacturer copay cards from Eli Lilly typically reduce out-of-pocket costs to as low as $25/month for up to 12 or 24 months.
  • Maximum manufacturer benefit caps generally range from $150 to $225 per month ($1,800 to $2,100 per calendar year).
  • Subject to pharmacy benefit manager (PBM) tier placement and your plan deductible requirements.
Prescriber Action Plan: Ask your prescribing doctor to submit a comprehensive Prior Authorization (PA) packet confirming BMI qualification and comorbidity documentation to satisfy plan coverage rules.

PA requirement notes: Approval typically requires documented BMI ≥30 or BMI ≥27 with at least one metabolic comorbidity, plus notes on prior lifestyle intervention attempts.

Need a prescriber to file a Prior Authorization?

Transparency & Compliance Notice: Out-of-pocket estimates are educational benchmarks reflecting published manufacturer coupon guidelines, wholesale acquisition cost benchmarks, and commercial health plan rules as of 2026. TrimSoMo is an independent, non-commercial informational directory and has no financial affiliation with Novo Nordisk, Eli Lilly, or pharmacy benefit managers (PBMs). Final copays are determined solely by your employer contract, insurer deductible, and dispensing pharmacy.

Source: FDA.gov Public Records

Latest FDA warning letters

Recent GLP-1 warning letters FDA sent to telehealth companies, online sellers, compounders, and pharmacies.

2026-10-30
RonanRx
SemaglutideTirzepatide

FDA says the company's website and X posts made false or misleading claims that its compounded semaglutide and tirzepatide were FDA-approved, well-studied, American made, and farm-to-table, and that product labels suggested RonanRx was the compounder of those drugs "when in fact it is not."

2026-09-24
Cheap Medicine Shop
Semaglutide

FDA found www.cheapmedicineshop.com introducing unapproved and misbranded injectable semaglutide ("Semanext Injection") into interstate commerce without an approved application or adequate directions for use.

2026-09-23
Online Generic Medicine
Semaglutide

FDA says the website introduced unapproved and misbranded injectable semaglutide (Semanat Injection) into interstate commerce without FDA approval, adequate directions, or required prescription, violating FD&C Act sections 301, 502(f)(1), 503(b)(1), and 505(a).

2026-09-18
Empower Pharmacy
SemaglutideTirzepatide

FDA says the firm compounded semaglutide and tirzepatide products that "appear to be essentially copies" of FDA-approved drugs regularly and in inordinate amounts without valid individualized prescriber determinations, and prepared sterile products under insanitary conditions with significant CGMP violations.

2026-08-24
Tex Peptides
RetatrutideSemaglutide+1

FDA's July 2026 review of texpeptide.com found seven products, including semaglutide, tirzepatide, and retatrutide, to be unapproved new drugs offered without approved applications, violating FD&C Act sections 301(d) and 505(a).

CMS NPPES Registry

Find obesity medicine providers by state

Doctors and clinics listed with an obesity medicine specialty in the CMS NPI Registry. Specialty is self-reported, not a board certification.

All states directory
Frequently Asked Questions

GLP-1 Weight Management FAQs

Common questions about dosing options, BMI qualifications, and stopping medications.

The FDA has approved five GLP-1 receptor agonist medications for chronic weight management in adults with obesity or overweight: Wegovy (semaglutide injection), Zepbound (tirzepatide injection), Wegovy Tablets (oral semaglutide), Foundayo (oral orforglipron), and Saxenda (liraglutide injection). They are indicated alongside a reduced-calorie diet and increased physical activity.

Guides

Plain-English articles on stopping GLP-1s, BMI criteria, and compounded medications.

View all articles

How telehealth programs work:1. Read about medications2. Online clinician assessment3. Pharmacy fulfillment.

Learn how programs work